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ABSTRACT
Limbal stem cells are responsible for the continuous renewal of the corneal epithelium. The
destruction or dysfunction of these stem cells or their niche induces limbal stem cell deficiency
(LSCD) leading to visual loss, chronic pain, and inflammation of the ocular surface. To restore
the ocular surface in cases of bilateral LSCD, an extraocular source of stem cells is needed to
avoid dependence on allogeneic limbal stem cells that are difficult to obtain, isolate, and cul-
ture. The aim of this work was to test the tolerance and the efficacy of human adipose tissue-
derived mesenchymal stem cells (hAT-MSCs) to regenerate the ocular surface in two experimen-
tal models of LSCD that closely resemble different severity grades of the human pathology. hAT-
MSCs transplanted to the ocular surface of the partial and total LSCD models developed in rab-
bits were well tolerated, migrated to inflamed tissues, reduced inflammation, and restrained
the evolution of corneal neovascularization and corneal opacity. The expression profile of the
corneal epithelial cell markers CK3 and E-cadherin, and the limbal epithelial cell markers CK15
and p63 was lost in the LSCD models, but was partially recovered after hAT-MSC transplanta-
tion. For the first time, we demonstrated that hAT-MSCs improve corneal and limbal epithelial
phenotypes in animal LSCD models. These results support the potential use of hAT-MSCs as a
novel treatment of ocular surface failure due to LSCD. hAT-MSCs represent an available, non-
immunogenic source of stem cells that may provide therapeutic benefits in addition to reduce
health care expenses. STEM CELLS 2017;35:2160–2174
SIGNIFICANCE STATEMENT
Partial and total ocular limbal stem cell deficiency (LSCD) models in rabbits emulate, respec-
tively, mild and moderate-to-severe LSCD in humans. Herein, we show that human adipose
tissue-derived mesenchymal stem cells (hAT-MSCs) transplanted to the ocular surface of LSCD
rabbit eyes were well-tolerated, migrated to inflamed tissues, reduced inflammation, and
restrained the evolution of corneal neovascularization and opacity. Additionally, the hAT-MSCs
partially restored the corneal and limbal epithelial phenotypes. Thus, hAT-MSCs, which are read-
ily available and non-immunogenic, represent a potential novel therapy for human ocular sur-
face failure due to loss of functional limbal stem cells.
INTRODUCTION
The integrity of the corneal epithelium plays a
critical role in maintaining transparency and
visual function. Limbal stem cells, located in the
basal epithelium of the corneoscleral limbus,
are responsible for the continuous renewal of
the corneal epithelium [1–3]. Destruction or
dysfunction of limbal stem cells or their niche
induces limbal stem cell deﬁciency (LSCD),
which can be triggered by a multitude of condi-
tions such as chemical or thermal burns,
cicatrizing-autoimmune pathologies, infections,
and so on. LSCD is characterized by the inva-
sion of conjunctival epithelium onto the cornea,
transforming it into an opaque, vascularized,
and defective epithelium. This usually results in
chronic pain, persistent ocular surface inﬂam-
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REGENERATIVE MEDICINE
The treatment of choice for unilateral cases of LSCD is
cultivated limbal epithelial transplantation (CLET) in which
autologous limbal epithelial cells, including stem cells, are har-
vested from the contralateral healthy eye and cultured to
expand the stem cell population before transplantation [6–8].
However, the high prevalence of bilateral cases makes alloge-
neic CLET, accompanied by essential immunosuppression, the
treatment of choice despite the increased risk of patient mor-
bidity and medical expenses [8]. Therefore, the use of an extra-
ocular source of stem cells would be desirable to avoid
dependence on allogeneic limbal stem cells, which are difﬁcult
to obtain, isolate, and culture and which can induce immune
rejection.
In recent years, the use of mesenchymal stem cells (MSCs)
has tremendously increased in cell therapy treatments [9–12]
because they are relatively easy to obtain from a variety of tissue
types, including bone marrow (BM), adipose tissue (AT), umbilical
cord, etc. MSCs have the capacity to differentiate toward meso-
dermal and non-mesodermal cell lineages [13], and importantly,
they also possess immunomodulatory and non-immunogenic
properties [14], obviating the need for immunosuppression.
There is abundant evidence from both in vitro and in vivo
studies regarding the potential use of BM-derived MSCs (BM-
MSCs) for ocular surface regeneration. All published data have
reported promising results in animal models and have demon-
strated signiﬁcant corneal regeneration, improved corneal trans-
parency, and rapid healing associated with the restoration of
vision [11, 15, 16]. AT is another source of MSCs (AT-MSCs) and
is more accessible, and more cost-effective, and a safer source
of MSCs than BM [17]. Recent studies have provided new
insights about the beneﬁcial role that AT-MSCs could have in
corneal epithelial regeneration. Our research group and others
have demonstrated that AT-MSCs express corneal epithelial
markers under basic culture conditions, suggesting that these
cells may have some inherent properties to regenerate the cor-
neal epithelium [18, 19]. In experimental models of LSCD,
administration of AT-MSCs subconjunctivally [20], topically
[21–23], or overlaid on scleral contact lenses or nanoﬁber scaf-
folds [24, 25] promotes regeneration of the corneal epithelium.
Additionally, a case report in which AT-MSCs were applied topi-
cally to a patient with persistent sterile epithelial defects sup-
ports the potential beneﬁt of this modality [26].
The success or the failure of any new therapy clearly
depends on the severity of the target pathology, and there-
fore, it is necessary to develop animal models that accurately
resemble the different progressive grades of the human dis-
eases. In this regard, we report here the development of two
animal models of LSCD that resemble the human progressive
grades of severity. With these models, we report not only the
changes in the clinical signs before and after AT-MSC trans-
plantation but also the expression proﬁles of corneal, limbal,
and conjunctival molecular markers. The aim of this work was
to test the tolerance and the efﬁcacy of human AT-MSCs to
regenerate the ocular surface in in vivo experimental models
that closely resemble human LSCD pathology.
MATERIALS AND METHODS
This study was approved by the IOBA Research Committee
and the Ethics and Animal Care Committees of the University
of Valladolid. All procedures followed the guidelines of the
Declaration of Helsinki for research involving human tissues
and the standards of Association for Research in Vision and
Ophthalmology as provided in the Statement for the Use of
Animals in Ophthalmic and Visual Research.
Isolation, Expansion, and Characterization of hAT-MSCs
Subcutaneous human AT was provided by a medical aesthetic
clinic (Europa Clinic, Valladolid, Spain) after a liposuction proce-
dure on a single subject who provided written informed con-
sent. Cells were isolated using the procedure described by Zuk
et al. [27]. The lipoaspirate was digested at 378C for 30 minutes
with 0.075% collagenase type I (Life Technologies, Inchinnan,
UK, http://www.lifetechnologies.com), incubated with 160 mM
NH4Cl erythrocyte lysing buffer (Sigma-Aldrich, St. Louis, MO,
http://www.sigmaaldrich.com) and ﬁltered through 100 mm
and 40 lm mesh ﬁlters (BD Falcon, Franklin Lakes, NJ, https://
www.bdbiosciences.com). Cells were cultured until passage 3–
4, in low-glucose (1 g/L) Dulbecco’s modiﬁed Eagle’s medium
(DMEM), GlutaMAX, 1 mM sodium pyruvate (Life Technologies),
10% fetal bovine serum (FBS) (Life Technologies), 100 U/mL
penicillin, and 100 lg/mL streptomycin (Life Technologies) at
378C, 5% CO2, and 95% humidity. Cell passages were made at a
density of 3,000–6,000 cells per square centimeter when cul-
tures reached 90% of conﬂuence. The cells were characterized
as described previously [18] in accordance with the Interna-
tional Society for Cellular Therapy (ISCT) position statement
[28].
hAT-MSC Culture on Amniotic Membranes
Before the seeding, P3–4 hAT-MSCs were labeled with 50-bromo-
20-deoxyuridine (BrdU, BD Biosciences, San Jose, CA, https://www.
bdbiosciences.com). hAT-MSCs at 70% conﬂuence were incubated
with 10 mM BrdU in culture medium (200 mL/cm2) for 24 hours at
378C. Human amniotic membrane (AM) was obtained from cesar-
ean section after written informed consent was obtained and pro-
vided by San Francisco Clinic (Leon, Spain). Each AM was
processed using the procedure described previously by Tseng [29]
with some modiﬁcations. The AMs were received in physiological
saline solution containing antibiotics, cut into pieces of approxi-
mately 4 cm 3 4 cm, and stored in DMEM with glycerol (Sigma-
Aldrich) (1:2) at 2808C. Immediately before use, the AMs were
thawed, washed with Hank’s balanced salt solution (HBSS, Life
Technologies) three times for 10 minutes, and treated with 0.25%
trypsin–ethylenediaminetetraacetic acid (Life Technologies) for 10
minutes at room temperature. After that, the trypsin was inacti-
vated with FBS, and the AMs were scraped to remove the epithe-
lium and cut into 2 cm 3 2 cm pieces. hAT-MSCs (2.5 3 105)
were seeded onto the AM pieces in 250 mL of culture medium
and allowed to adhere. After 2 hours, 200 mL/cm2 of culture
medium was added.
In Vivo Models of LSCD
The ﬁrst LSCD model was created with a surgical 1808 limbal
peritomy (superior and temporal, n5 15) performed by cres-
cent knife, removing 1–1.5 mm of the adjacent conjunctiva to
ensure the total removal of the limbal niche. Hereinafter, this
is referred to as the “partial LSCD.” The second LSCD model
was similarly created but with a 3608 limbal peritomy (n5 12).
It is referred to as the “total LSCD.” Topical anti-inﬂammatory
and antibiotics including two drops of Maxitrol (3,500 IU/mL
neomycin, 6,000 IU/mL polymyxin B, and 1 mg/mL dexametha-
sone, Alcon, Barcelona, Spain, https://www.alcon.es); 3 mg/g
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tobramycin ointment (Tobrex, Alcon), systemic analgesia
(0.02 mg/kg buprenorphine, Buprex, Indivior, Bristol, UK,
http://www.indivior.com) and antibiotics (5 mg/kg enroﬂoxacin,
Alsir, Esteve, Barcelona, Spain, https://www.esteve.es) were
administered daily for 5 days.
The partial and total LSCD models were created in adult
female New Zealand white rabbits (Oryctolagus cuniculus).
The eyes were divided in ﬁve groups: Group 0, healthy eyes
(n5 6); Group 1, partial LSCD without treatment (n5 6) in
eyes that were contralateral to Group 0; Group 2, partial LSCD
transplanted with AM without hAT-MSCs (n5 3); Group 3, par-
tial LSCD transplanted with hAT-MSCs on AM (n5 6); Group 4,
total LSCD without treatment (n5 6); and Group 5, total LSCD
transplanted with hAT-MSCs on AM (n5 5) (Supporting Infor-
mation Table S1). The rabbits were anesthetized by intramuscu-
lar injection of 50 mg/kg ketamine (Imalgene 1000, Merial,
Lyon, France, http://merial.com) and 7 mg/kg xylazine (Rom-
pun, Bayer, Leverkusen, Germany, http://www.bayer.com), com-
plemented with topical ophthalmic anesthesia (1 mg/mL
tetracaine and 4 mg/mL oxybuprocaine, Colicursi, Alcon). Denu-
dation of corneal surface was performed by rubbing with a cot-
ton swab soaked in n-heptanol (Sigma-Aldrich) for 1 minute
followed by a surgical limbal peritomy (1808 or 3608). Three
weeks after injury, AM without hAT-MSCs was transplanted to
the ocular surface of three animals with partial LSCD. AM with
hAT-MSCs was transplanted to the ocular surface of 11 animals
(six of the partial LSCD model and ﬁve of the total LSCD) and
sutured with Surgipro II 7.0 polypropylene suture (Tyco Health-
care Group, Cork, Ireland, http://www.tyco.com). After transplan-
tation, the eyelids were closed with a partial tarsorrhaphy
(leaving enough space to apply topical drugs) using 5.0 silk
sutures (AJL Ophthalmic, Alava, Spain, http://ajlsa.com). Triamcin-
olone (40 mg, Trigon Depot, Bristol-Myers Squibb, Madrid, Spain,
http://www.bms.es) was administered by transeptal injection.
Topical anti-inﬂammatory and antibiotics and systemic analgesics
and antibiotics were administered daily for 5 days. Two weeks
after the transplantation, the eyelids were re-opened. Eleven
weeks after the creation of the injury, the animals were eutha-
nized by intravenous injection of 200 mg/kg pentobarbital
sodium (Dolethal, Vetoquinol, Lure, France, http://www.vetoqui-
nol.com). Samples of cornea and limbus were collected and ﬁxed
in 4% formaldehyde (Panreac, Barcelona, Spain, http://www.pan-
reac.es) for histopathology analysis.
Clinical Evaluation
Corneal neovascularization, corneal opacity, and corneal epithe-
lial defects (stained with sodium ﬂuorescein, Colircusi Fluotest,
Alcon) were clinically examined weekly by slit lamp (Kowa SL-15,
Kowa Medicals, Tokyo, Japan, http://www.kowamedical.com) and
assessed from 0 to 4 by two different researchers [30]. Neovas-
cularization and epithelial defects were scored using the follow-
ing scale: 0, none; 1, area 1=4; 2, 1=4< area 1=2; 3,
1=2< area 3=4; and 4, area> 3=4 (Supporting Information Table
S2). In the total LSCD model, conjunctival invasion was similarly
evaluated and also measured in millimeters. Additionally, neoves-
sel length was scored in millimeters as well as with the Efron
scale [31]. Corneal opacity was scored as follows: 0, none; 1,
mild; 2, moderate; 3, severe, pupil seen faintly; and 4, severe,
pupil not visible (Supporting Information Table S2). Furthermore,
epithelial defect areas were measured by the image-processing
program Image J (http://rsb.info.nih.gov/ij/). In the total LSCD
model, the cornea was divided in ﬁve different areas, and each
area was scored for each clinical sign.
Histopathology
Histopathological analysis was performed in all eyes at the end of
follow-up to evaluate the degree of damage created in the cornea
and the limbus and recovery after transplantation. Fixed tissue
samples were processed, embedded in parafﬁn, and cut in 4 mm
slices with a microtome. The tissue sections were prepared in the
sagittal plane of the central cornea so that each slice included the
superior limbus, central cornea, and inferior limbus. In total, 18–
20 sections were cut from each sample, and six of them were
used for histopathology. The others were used for immunoﬂuores-
cence microscopy. Periodic acid-Schiff staining was performed to
show goblet cells in the limbal or corneal epithelium and inﬂam-
matory cells and blood vessels in the corneal and limbal stroma.
The healthy contralateral eyes of six rabbits were used as the con-
trol group (Group 0). The presence of inﬂammatory cells was
semi-quantiﬁed using the following scale: 0, absence; 1, low
amount; 2, moderate amount; and 3, high amount.
Immunofluorescence Microscopy
Histological sections were permeabilized with phosphate-
buffered saline (PBS) (Life Technologies) containing 0.3% Triton
X-100 (Sigma-Aldrich). Afterward, samples were incubated for 1
hour with 5% donkey or goat serum (Sigma-Aldrich) in PBS at
room temperature to block nonspeciﬁc binding. Following that,
they were incubated at 48C overnight with cell-speciﬁc mono-
clonal antibodies against the corneal epithelial markers CK3
[32] and E-cadherin [33], the limbal epithelial markers CK15
[34] and p63 [35], and the conjunctival epithelial marker CK7
[36] diluted in blocking buffer (Supporting Information Table
S3). Afterward, the samples were incubated for 1 hour at room
temperature in darkness with the secondary antibody (PECy5
goat anti-mouse) diluted in PBS (Supporting Information Table
S3). Immunoﬂuorescence against BrdU (AntiBrdU-DyLight650;
Supporting Information Table S3) was performed to locate hAT-
MSCs. The samples were ﬁrst incubated with 2 M HCl (Panreac)
at room temperature for 30 minutes to enable access of the
antibody to the DNA, and neutralized with sodium borate
buffer (10 mM NaOH, pH 8.5). Finally, cell nuclei were counter-
stained with Hoechst (Sigma-Aldrich) and visualized in an
inverted ﬂuorescence microscope (DM4000B Leica, Wetzlar,
Germany, http://www.leica.com). Primary antibodies were omit-
ted in negative control studies. Samples in which CK7 expres-
sion were studied were also incubated with lectin-FITC from
Helix Pomatia (1:500, Sigma-Aldrich) for 30 minutes to show
goblet cell mucin. The healthy contralateral eyes of six rabbits
were used as controls (Group 0). Twelve sections from each
experimental group were used to study the expression of each
marker. The percentage of p63-positive cells was calculated in
the tissues of the different groups.
Statistical Analysis
Under guidance of the IOBA Statistical Unit (Dr. Itziar Fernan-
dez), mean6 SEM values were calculated and analyzed using
the Statistical Procedures for the Social Sciences (SPSS 18.0,
IBM Corporation, Somers, NY, https://www.ibm.com). Two-
sided p .05 were considered statistically signiﬁcant. For
analysis of qualitative variables, the Kruskal-Wallis test for
more than two groups or the Mann-Whitney U test for two
groups were used. The Friedman test for more than two
groups or the Wilcoxon test for two groups were used to
compare values over time. For quantitative data, statistical
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signiﬁcance was determined by two-way factorial repeated
measures analysis of variance. The comparison between two
groups was made using Student’s t test. Spearman’s correla-
tion coefﬁcients were used to correlate the presence of
inﬂammatory cells and hAT-MSCs.
RESULTS
Clinical Analysis
Partial LSCD Model. In the partial LSCD model, where the
limbectomy was localized to the superior and temporal
limbus, neovascularization and corneal opacity were present
from 1 week after injury (Fig. 1A, 1B). The neovessels
appeared mainly in the superior area of the cornea. Epithelial
defects were partially resolved during the ﬁrst 2 weeks (Fig.
1B). Three weeks after injury, AMs without cells were trans-
planted to the ocular surface of three rabbits, and AMs with
hAT-MSCs were transplanted to six rabbits. There were no dif-
ferences in clinical signs between rabbits in the partial LSCD
model without treatment and those transplanted with AM
but without hAT-MSCs (Supporting Information Fig. S1). In the
six animals of the AM1 hAT-MSC transplanted group, before
transplantation, neovessels covered between 1=4 and 1=2 of the
Figure 1. Ocular surface evaluation in the partial limbal stem cell deﬁciency model without and with human adipose tissue-derived mesenchymal
stem cells (hAT-MSCs). (A): Representative images from the control and hAT-MSC transplanted group. Red arrowheads, neovascularization sites. (B):
Neovascularization and corneal opacity developed during the ﬁrst weeks after the creation of the injury. Epithelial defects were partially resolved dur-
ing the ﬁrst 2 weeks. The clinical signs did not change after the hAT-MSC transplantation. There were no signiﬁcant differences between the non-
transplanted and the transplanted groups. Data for Week 0 were acquired immediately after the injury. Data for Week 3 were acquired before trans-
plantation. Abbreviations: AM, amniotic membrane; hAT-MSCs, human adipose-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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total cornea, corneal opacities were moderate, and epithelial
defects were smaller than 1=4 of the total cornea. The clinical
signs did not change after the hAT-MSC transplantation (Fig.
1). While there were no signiﬁcant differences between the
non-transplanted and the AM1 hAT-MSC transplanted group
with respect to neovascularization, corneal opacity, and epi-
thelial defects (Fig. 1), these results indicated that hAT-MSCs
were well tolerated on the ocular surface of the partial LSCD
model.
Total LSCD Model. In rabbits with total LSCD, neovasculariza-
tion and corneal opacity developed during the ﬁrst weeks
after the injury (Fig. 2A, 2B). Epithelial defects partially
Figure 2. Ocular surface evaluation in the total limbal stem cell deﬁciency (LSCD) model without and with human adipose tissue-
derived mesenchymal stem cells (hAT-MSCs). (A): Representative images from the control and hAT-MSC transplanted group. (B): In the
control total LSCD group, there was a signiﬁcant increase in neovascularization, neovessel length, and corneal opacity after Week 3.
However, these clinical signs did not increase after hAT-MSC transplantation. Neovessel length was higher in the control group than in
the hAT-MSC transplanted group. Two of the six animals of the control group, and one of the ﬁve animals of the transplanted group
had a thick conjunctival invasion on the corneal surface, but overall it was not signiﬁcant. Data for Week 0 were acquired immediately
after the creation of the injury. Data for Week 3 were acquired before transplantation. *, p .05. Abbreviations: AM, amniotic mem-
brane; hAT-MSCs, human adipose tissue-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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recovered during the ﬁrst 2 weeks (Fig. 2B). Three weeks after
the creation of the injury, hAT-MSCs seeded onto AMs were
transplanted to the ocular surface of ﬁve rabbits (one animal
was excluded for transplantation because it developed a sym-
blepharon, an adhesion of the palpebral conjunctiva to the
bulbar conjunctiva). In the total LSCD group without treat-
ment, there was a signiﬁcant increase in neovascularization,
especially between Week 3 and Weeks 5, 6, 7, 8, and 10
(p5 .046, p5 .043, p5 .028, p5 .028, and p5 .046, respec-
tively; Fig. 2B). However, the increase in neovascularization
was not present after hAT-MSC transplantation. Neovessel
length was higher in the total LSCD group without treatment
than in the hAT-MSC transplanted group during Weeks 5, 6, 7,
8, 9, and 11 (p5 .041, p5 .034, p5 .011, p5 .012, p5 .046,
and p5 .04, respectively; Fig. 2B). Furthermore, when vessel
length was scored on the Efron scale, there was a signiﬁcant
increase in length for the non-transplanted group between
Week 3 and Weeks 5–11 (p5 .042, p5 .028, p5 .028,
p5 .027, p5 .028, p5 .028, and p5 .028, respectively),
whereas in the transplanted group, this increase was not pre-
sent (Fig. 2B).
There was an increase in corneal opacity from Week 3 to
Weeks 4–9 (p5 .028, p5 .028, p5 .028, p5 .028, p5 .028,
and p5 .046, respectively) in the non-transplanted group (Fig.
2B), but this was absent from the hAT-MSC transplantation
group. In the non-transplanted group, there was a thick con-
junctival invasion on the corneal surface in two of the six ani-
mals. A similar invasion occurred in only one of the ﬁve
animals in the transplanted group. However, the conjunctival
invasion on the cornea was not statistically signiﬁcant in any of
the groups (Fig. 2B). While the epithelial defect scores and
areas for the non-transplanted group were greater than for the
transplanted group, the differences were not statistically signiﬁ-
cant (Fig. 2B). Collectively, these results indicated that hAT-MSC
transplantation prevented the progression of LSCD (Fig. 2).
Histopathology
Partial LSCD Model. At the end of the follow-up at Week
11, 4–5 epithelial layers were present in the central cornea
and 6–7 in the superior and inferior limbus of the control
non-LSCD eyes (Fig. 3). The same number of layers was also
present in the partial LSCD group without treatment. Goblet
cells, which are present in the normal conjunctival epithelium
but not in the cornea or limbus, occurred in the superior and
inferior limbal epithelium of the untreated partial LSCD
model. They were also present in the limbus of eyes trans-
planted with AM and transplanted with AM1 hAT-MSCs (Fig.
3). Inﬂammatory lymphocytes were present in the superior
and inferior limbal stroma of the untreated partial LSCD eyes,
partial LSCD eyes with AM, and partial LSCD eyes with
AM1 hAT-MSCs. However, the central cornea of all groups
was normal in appearance, containing no goblet cells, inﬂam-
mation, or neovessels. There were no histological differences
among the three groups of the partial LSCD model. Further-
more, there were no adverse reactions in the tissues after the
transplantation of AM1 hAT-MSCs, which conﬁrmed that the
ocular surface was highly tolerant of these cells (Fig. 3; Sup-
porting Information Fig. S2).
Total LSCD Model. In the untreated total LSCD group at the
end of the follow-up at Week 11, there were only 2–3
epithelial layers in the central cornea compared with the 4–5
layers in the non-LSCD control eyes (Fig. 3). Similarly, the 2–3
epithelial layers in the limbus were less than the 6–7 layers
present in the non-LSCD eyes. Furthermore, the epithelium of
the non-transplanted eyes was disorganized, and goblet cells
were present in the superior and inferior limbal epithelium,
indicating the occurrence of conjunctival in-growth (Fig. 3). In
two of the six untreated animals with total LSCD, goblet cells
were present in the central cornea. Inﬂammatory cells (lym-
phocytes) and disorganization of the stromal ﬁbers in the
superior and inferior limbal stroma and in the central cornea
demonstrated that the total LSCD model was more severe
than the partial LSCD model.
As in the non-transplanted group, the AM1 hAT-MSC
transplanted group at Week 11 had fewer epithelial layers
than in the healthy tissues. Moreover, goblet cells were pre-
sent in the limbal epithelium and inﬂammatory cells were in
the limbal stroma. In one of the animals, goblet cells and
inﬂammation were also noted in the central cornea. However
overall, the hAT-MSC transplanted eyes had fewer inﬂamma-
tory cells and less disorganization in the stroma of the central
cornea in comparison with the non-transplanted group (Fig. 3;
Supporting Information Fig. S2).
hAT-MSC Localization
The hAT-MSCs labeled with BrdU were located in the inﬂamed
areas of the superior and inferior limbal stroma 8 weeks after
transplantation in both partial and total LSCD models (Fig. 3;
Supporting Information Fig. S2). The eyes with a more promi-
nent inﬂammatory inﬁltrate also had more hAT-MSCs. The
hAT-MSCs were located in the central cornea of the animals
with inﬂammation in this area. The correlation between the
amount of hAT-MSCs transplanted and the level of inﬂamma-
tion in the cornea was signiﬁcant (r5 0.810; p5 .003; Sup-
porting Information Fig. S2).
Phenotypic Analysis
The presence of ﬁve phenotype-speciﬁc marker proteins was
assessed at the end of the 11-week follow-up period. The
presence of CK3, a speciﬁc marker of corneal epithelial cells
[32], increased in the limbal epithelium of the untreated
partial LSCD model (Fig. 4). However, in the partial LSCD
model transplanted with AM, the expression of CK3 was
reduced. In the partial LSCD model transplanted with hAT-
MSCs, CK3 expression was similar to the healthy control
eyes. CK3 was not expressed in the epithelium of the
untreated total LSCD model (Fig. 4). However, it was
expressed in the corneal and limbal epithelia of the total
LSCD model transplanted with AM1 hAT-MSCs (Fig. 4; Sup-
porting Information Table S4).
The expression of E-cadherin, another marker of corneal
epithelial cells [33], did not change in the partial LSCD model
(Fig. 5). In the untreated total LSCD model, E-cadherin was
not expressed. However, it was present in the corneal and
limbal epithelia of the total LSCD model transplanted with
AM1 hAT-MSCs (Fig. 5; Supporting Information Table S4).
CK15 (Fig. 6) and p63 (Fig. 7), markers of limbal epithelial
stem cells [34, 35], were lost in the damaged superior limbus
of the untreated partial LSCD model and in the partial LSCD
eyes transplanted with AM alone. However, expression of
both markers was partially restored in the superior limbus of
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Figure 3. Periodic acid-Schiff and 50-bromo-20-deoxyuridine (BrdU) staining in control, partial limbal stem cell deﬁciency (LSCD), and total
LSCD eyes with and without amniotic membrane (AM) or AM1 human adipose tissue-derived mesenchymal stem cell (hAT-MSC) transplants.
Goblet cells (purple) in the limbal epithelium and inﬂammatory cells (dark purple) were present in the limbal stroma of the ﬁve study groups
(partial LSCD without treatment, partial LSCD with AM, partial LSCD with hAT-MSCs, total LSCD without treatment, and total LSCD with hAT-
MSCs) at the end of the follow-up period (11 weeks). In the partial LSCD model, there were no differences between the non-transplanted and
the transplanted groups. In the total LSCD model, the non-transplanted group presented fewer epithelial layers, a disorganized cornea (epithe-
lium and stroma) and inﬂammatory cells in the stroma of the central cornea. However, the hAT-MSC transplanted eyes had fewer inﬂammatory
cells and less disorganization in the stroma of the central cornea. BrdU-containing hAT-MSCs (red) were located in the inﬂamed areas of the
limbal stroma (superior and inferior) 8 weeks after transplantation in both partial and total LSCD models. Blue, nuclei. Scale bar5 50 mm.
Abbreviations: AM, amniotic membrane; hAT-MSCs, human adipose-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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the partial LSCD transplanted with AM1 hAT-MSCs (Support-
ing Information Table S4; Fig. S3). In the limbal epithelium of
the healthy control eyes, the percentage of p63-positive cells
was 47.7%6 3.7% (45.5%6 3.1% in the superior limbus and
50.1%6 7.3% in the inferor limbus). In the limbal epithelium
of the partial LSCD model, the percentage of p63-positive
cells was signiﬁcantly lower than in the control healthy group
(16%6 3.3% vs. 47.7%6 3.7%; p< .001). This decrease was
higher in the damaged area (superior limbus, 3%6 2%;
p< .001) than in the inferior limbus (25.6%6 4%; p5 .006) in
comparison with the same area of the control group. Very
similar results were observed in the limbal epithelium of the
animals transplanted with cell-free AM. The percentage of
p63-positive cells was 16.6%6 5.9% in the total limbus,
Figure 4. Immunoﬂuorescence microscopy of CK3 expression, a corneal epithelial marker, in the ocular surface of the partial and total
limbal stem cell deﬁciency (LSCD) models at the end of the follow-up period. Compared with the control, CK3 expression (yellow)
increased in the limbal epithelium of the untreated partial LSCD model. In the partial LSCD model transplanted with amniotic membrane
(AM), the expression of CK3 was reduced in the corneal epithelium. However, in the partial LSCD model after the AM1 human adipose
tissue-derived mesenchymal stem cell (hAT-MSC) transplantation, it was similar to the healthy control group. CK3 was not expressed in
the epithelium of the untreated total LSCD model. However, it was expressed in the corneal and limbal epithelia of the total LSCD
model transplanted with AM1 hAT-MSCs. Nuclei, blue. Representative images from each group. Scale bar5 100 mm. Abbreviations: AM,
amniotic membrane; hAT-MSCs, human adipose-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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4.8%6 2.2% in the superior limbus, and 37.8%6 11.1% in the
inferior limbus. These percentages were signiﬁcantly lower
than for the healthy control group in the total limbus
(p5 .001) and in the superior limbus (p< .001), but not dif-
ferent for the inferior limbus or in comparison with the
untreated group. The expression of positive cells for p63 was
signiﬁcantly lower in the hAT-MSC transplanted group in com-
parison with the healthy control group (35.7%6 1.8% vs.
47.7%6 3.7%, p5 .038). However, the expression of p63 was
partially restored in the hAT-MSC transplanted group (35.7%6
1.8%), especially in the superior limbus (36.3%6 2.7%), showing
a signiﬁcant increase in comparison with the untreated group
(p< .001 for total and superior limbus) and with the AM-
transplanted group (p5 .032 for total limbus and p< .001 for
superior limbus) (Supporting Information Fig. S3). In the total
LSCD model, the expression of CK15 (Fig. 6) and p63 (Fig. 7;
Supporting Information Fig. S3) was lost in the limbal epithe-
lium, but it was partially recovered in the AM1 hAT-MSC
Figure 5. Immunoﬂuorescence microscopy of E-cadherin expression, a corneal epithelial cell marker, in the ocular surface of the partial
and total limbal stem cell deﬁciency (LSCD) models at the end of the follow-up period. Compared with the control, the expression of E-
cadherin (yellow) did not change in the partial LSCD model. In the untreated total LSCD model, E-cadherin was not expressed, but it
was present in the corneal and limbal epithelia of the total LSCD model transplanted with amniotic membrane1 human adipose tissue-
derived mesenchymal stem cells. Nuclei, blue. Representative images from each group. Scale bar5 100 mm. Abbreviations: AM, amniotic
membrane; hAT-MSCs, human adipose-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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transplanted group (Supporting Information Table S4; Fig. S3).
Additionally, CK15 was expressed in the corneal epithelium of the
AM1 hAT-MSC transplanted group. In the total LSCD model, the
percentage of p63-positive cells was signiﬁcantly lower in the
untreated group than in the healthy control group (3.7%6 1.2%
vs. 47.7%6 3.7% in the total limbus, p< .001; 4.5%6 2.1% vs.
45.5%6 3.1% in the superior limbus, p< .001; and 2.9%6 1.4%
vs. 50.1%6 7.3% in the inferior limbus, p5 .001). The hAT-MSC
transplanted group had a lower percentage of cells expressing
p63 than the healthy control group (19.1%6 3.6% vs. 47.7%6
3.7% in the total limbus, p< .001; 13%6 2.5% vs. 45.5%6 3.1%
in the superior limbus, p5 .001; and 24.7%6 6.3% vs. 50.1%6
7.3% in the inferior limbus, p5 .044). However, the percentage
of p63-positive cells was partially restored in the hAT-MSC trans-
planted group, especially in the inferior limbus, in comparison
with the untreated group (p5 .001 for total limbus, p5 .048 for
superior limbus, and p5 .011 for inferior limbus) (Supporting
Information Fig. S3).
Figure 6. Immunoﬂuorescence microscopy of CK15 expression, a limbal stem cell marker, in the ocular surface of the partial and total
limbal stem cell deﬁciency (LSCD) models at the end of the follow-up period. CK15 expression (yellow) was lost in the damaged superior
limbus of the untreated partial LSCD model and in those transplanted with amniotic membrane (AM). There was a partial recovery in
the human adipose tissue-derived mesenchymal stem cell (hAT-MSC) transplanted group. In the total LSCD model, the expression of
CK15 was lost in the limbal epithelium, but it was partially recovered in the corneal and limbal epithelia of the AM1 hAT-MSC trans-
planted group. Nuclei, blue. Representative images from each group. Scale bar5 100 mm. Abbreviations: AM, amniotic membrane; hAT-
MSCs, human adipose-derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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The conjunctival epithelial cell marker CK7 [36] was
expressed in the conjunctival epithelium and in some cells of
the limbal epithelium in the healthy eyes (Supporting Infor-
mation Fig. S4). There were no differences in CK7 expression
among the different control and experimental groups of the
partial and total LSCD models (Supporting Information Fig. S4;
Table S4). Mucins in goblet cells stained by lectin were pre-
sent in the conjunctiva while some were located in the limbus
of healthy eyes. Additionally, there was a diffuse staining on
the surface of the conjunctival and limbal epithelia, indicating
the presence of secreted mucins. Except as noted below,
there were no differences in the staining of mucins by lectin
among the different control or experimental groups of either
the partial and total LSCD models. In the partial LSCD model,
the central cornea remained free of lectin-stained goblet cells.
In two of the six animals with untreated total LSCD, goblet
cells were present in the central cornea. However, only one
animal of the total LSCD group transplanted with AM1 hAT-
Figure 7. Immunoﬂuorescence microscopy of p63 expression, a limbal stem cell marker, in the ocular surface of the partial and total
limbal stem cell deﬁciency (LSCD) models at the end of the follow-up period. The expression of p63 (yellow) was lost in the damaged
superior limbus of the untreated partial LSCD model and in the amniotic membrane (AM)-transplanted eyes. There was partial recovery
in the AM1 human adipose tissue-derived mesenchymal stem cell (hAT-MSC) transplanted group. In the total LSCD model, p63 expres-
sion was lost in the limbal epithelium, but it was partially recovered in the AM1 hAT-MSC transplanted group. Nuclei, blue. Representa-
tive images from animals of each group. Scale bar5 100 mm. Abbreviations: AM, amniotic membrane; hAT-MSCs, human adipose-
derived mesenchymal stem cells; LSCD, limbal stem cell deﬁciency.
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MSCs had goblet cells in the central cornea (Supporting Infor-
mation Fig. S4).
DISCUSSION
To study the tolerance and efﬁcacy of the hAT-MSCs trans-
planted onto the ocular surface, it was ﬁrst necessary to
develop an in vivo experimental model that closely resembles
human LSCD disease. To that end, we used surgical limbec-
tomy to develop two different rabbit models that mimicked
the progressive LSCD grades of severity in humans. We chose
rabbit to develop our models because the rabbit cornea is
large enough to perform surgeries, the histological structures
of the eye are similar to human eyes [37], and many of the
in vivo LSCD models have been developed using rabbits
[38–40].
By performing a n-heptanol-based denudation of the cor-
neal surface followed by a surgical 1808 limbectomy in the
superior and temporal ocular surface quadrants, we devel-
oped a partial, mild LSCD model. Clinically and pathologically,
the model resembled mild LSCD in humans [4, 5]. In our rab-
bits, neovascularization and corneal opaciﬁcation occurred
during the ﬁrst 3 weeks after the generation of the injury, but
the epithelial defects arising from the heptanol denudation of
the cornea partially recovered during the ﬁrst 2 weeks, as
also described by Chen and Tseng [41]. In our study, from the
third week after induction of partial LSCD, even in the
absence of further treatment, the clinical signs became stable
and were maintained throughout the follow-up. Based on
these ﬁndings and those of others [42], we selected the third
week for the time of transplantation.
We generated a total LSCD model by performing n-hepta-
nol-based denudation of the corneal surface followed by a
3608 limbectomy. This model clinically and pathologically
resembled moderate-to-severe LSCD in humans [4, 5]. Neo-
vascularization and corneal opaciﬁcation were more severe
than in the partial LSCD, and they developed over the ﬁrst 3
weeks after the creation of the injury, as other authors have
noted [23, 43–45]. Moreover, the epithelial defects underwent
partial recovery during the ﬁrst 2 weeks and were maintained
during the follow-up period, as reported by others [30, 46]. In
two of the six untreated rabbits, a thick conjunctival invasion
occurred on the corneal surface, indicating that the total
LSCD model was more severe than the partial LSCD model, as
we expected. In addition, these results conﬁrm that the lim-
bus acts as a physical barrier between the conjunctiva and
the cornea.
AMs without cells were transplanted to the ocular surface
of three rabbits with partial LSCD to make sure that an
adverse reaction would not occur after surgical suturing. The
clinical signs did not change after the AM transplantation in
comparison with the partial LSCD group without AM. Due to
the lack of changes in the clinical signs after the AM trans-
plantation, we decided that it was not necessary to include a
group transplanted with cell-free AM in the total LSCD model.
According to our results, previous in vivo studies did not ﬁnd
signiﬁcant differences in the evolution of clinical signs in ani-
mals with untreated LSCD or when treated with cell-free AM
[40, 47]. Nevertheless, due to its re-epithelizing, anti-inﬂam-
matory, antiﬁbrotic, and anti-angiogenic properties, cell-free
AM transplantation is a procedure frequently performed in
patients with mild and/or partial LSCD to improve their clini-
cal situation [48, 49]. However, cell-free AM transplantation is
insufﬁcient for regeneration of the ocular surface in patients
with severe and/or total LSCD [50].
The clinical signs did not improve in the partial LSCD
model after hAT-MSC transplantation. The mildness of the
model could partially explain this lack of improvement. How-
ever, the fact that the clinical signs did not increase after the
hAT-MSC transplantation indicates that hAT-MSCs were well
tolerated in the rabbit ocular surface even without the use of
immunosuppression. These results agree with other studies in
which human MSCs were transplanted to the ocular surface
of mice [21], rats [22, 51], and rabbits [20, 24] without any
indications of rejection.
In eyes with total LSCD, the evolution of neovasculariza-
tion and corneal opaciﬁcation was restrained after hAT-MSC
transplantation. Although a proangiogenic role has been
described for MSCs [52], these cells seem to have anti-
angiogenic properties in the ocular surface. Decreases in neo-
vascularization and corneal opacity have been previously dem-
onstrated after the hAT-MSC administration [23–25]. In
addition, several authors have described the improvement of
these clinical signs after MSC administration by different
routes [25, 51, 53–56]. While the epithelial defects were
larger in the non-transplanted group than in the transplanted
group throughout the follow-up period, the differences were
not statistically signiﬁcant. However, other authors have noted
that hAT-MSCs contribute to the recovery of corneal epithe-
lium, even in humans [20–26]. Perhaps if the number of ani-
mals had been higher, signiﬁcant differences in epithelial
defects would have been more apparent between the differ-
ent experimental groups.
The presence of inﬂammatory cells was higher in the lim-
bal stroma of the total LSCD model than in the partial LSCD
model. In addition, the stroma was more disorganized in the
total LSCD model, indicating again that the total model was
more severe than the partial model, as shown by the clinical
evaluation. These data suggest that the partial limbectomy
produced a mild model of LSCD in rabbits. There were no his-
tological differences among the study groups of the partial
LSCD model. However, in the total LSCD model, there was a
decrease of inﬂammatory cells and an improvement of the
stromal organization in the AM1 hAT-MSC transplanted group.
These ﬁndings are consistent with the anti-inﬂammatory role
of hAT-MSCs delivered by different routes for corneal chemical
burn or in LSCD animal models [21–25]. Moreover, BM-MSCs
or MSCs isolated from the limbal stroma can reduce the
inﬂammation in the ocular surfaces [25, 55, 57, 58]. Some of
the molecules that are implicated in this anti-inﬂammatory
process are interleukin-10, transforming growth factor-b, and
Tumor necrosis factor-stimulated gene 6 (TSG-6) [57, 59, 60].
Goblet cells were present at the end of the follow-up in
the limbal epithelium of both partial and total LSCD models.
They were also present in the central cornea of three rabbits
from the total LSCD model (two in the non-transplanted
group; one in the hAT-MSC transplanted group), correspond-
ing with the thick conjunctival invasion of the corneal surface.
In general, at the end of the follow-up period, few goblet
cells were noted in the corneal epithelium of all study groups.
Our results are consistent with the decrease in goblet cell
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numbers described for human chemical burns [61] and in rab-
bits in the weeks after chemical injury [40, 62].
In both the partial and total LSCD models, hAT-MSCs
migrated to areas of the limbal stroma that contained many
inﬂammatory cells. Our results are consistent with the
migration of topically applied hAT-MSCs to the burned cor-
nea and limbus as described by other authors [21, 22].
Other groups have also demonstrated the migration of lim-
bal stromal MSCs or BM-MSCs to the damaged cornea and
limbus when they were applied by different routes [55, 58,
63]. On the other hand, some studies have reported that
AT-MSCs or BM-MSCs administered by subconjunctival injec-
tion did not migrate away from the injection site [21, 43].
Furthermore, some reports indicated that MSCs adminis-
tered systemically or intraperitoneally in a LSCD model exert
their therapeutic action without migration to the damaged
area [59]. One of the well-known signaling pathways that
regulate cell homing is mediated by C-X-C motif chemokine
12 or stromal cell-derived factor 1 (CXCL12/SDF-1) and its
receptor C-X-C chemokine receptor type 4 (CXCR4), which is
expressed by MSCs [64]. Under inﬂammatory conditions, tis-
sues secrete CXCL12/SDF-1 that attracts MSCs [65]. In nor-
mal conditions, CXCL12/SDF-1 is more abundant in the
limbal than in the corneal epithelium, and CXCR4 is
expressed in the limbal stroma rather than in the corneal
stroma [66, 67]. Although there is a lack of data about the
expression of these molecules in inﬂamed ocular surface tis-
sues, these factors could be implicated in the migration of
the AT-MSCs to the damaged cornea and limbus of our in
vivo models.
In our LSCD models, we analyzed by immunoﬂuores-
cence microscopy the molecular changes in the expression
proﬁles of corneal, limbal, and conjunctival cell markers. The
expression of the corneal epithelial cell marker CK3
increased in the limbus of the partial LSCD model, indicating
the possibility that limbal epithelial stem cells were differ-
entiating and migrating from the limbus to the central cor-
nea during the restoration of the corneal epithelium. In
contrast, the expression of CK3 decreased in the cornea of
the untreated total LSCD model in agreement with the data
published by other authors using different LSCD models [30,
46, 51, 68].
Although there were no clinical or histological differences
between the partial LSCD group without treatment and the
AM1 hAT-MSC transplanted group, there were some molecu-
lar changes. After AM1 hAT-MSC transplantation, CK3 was
expressed not only in the corneal epithelium, but also in the
limbal epithelium. These data suggest that hAT-MSCs contrib-
ute to recovery of the corneal epithelium by secreting factors
that promote the proliferation and differentiation of the
remaining limbal epithelial stem cells. This is consistent with
the increased expression of CK3 and/or CK12 in the corneal
epithelium after BM-MSC administration in corneal burn and
LSCD models [40, 51].
The expression of E-cadherin, an intercellular junction pro-
tein, decreased in the total LSCD model, indicating a possible
loss of intercellular junctions of the corneal epithelium. Our
results are consistent with the decrease in E-cadherin expres-
sion similar to that which occurs in defective development of
mouse corneal epithelium [69]. E-cadherin expression
increased in both the corneal and limbal epithelia of the total
LSCD group transplanted with AM1 hAT-MSCs. These data
indicate that hAT-MSCs contribute to the recovery of the cor-
neal epithelium. Similarly, the expression of connexin 43, a
gap junction protein, occurs after BM-MSC transplantation in
a different rabbit model of LSCD [40].
The expression of the limbal epithelial stem cell markers
CK15 and p63 was lost from the superior limbus of the partial
LSCD model and from the superior and inferior limbus of the
total LSCD model, as we expected. The loss of limbal stem
cell markers occurs in other LSCD models [51, 70]. However,
the expression of CK15 and p63 recovered in the limbal epi-
thelium of the partial and total LSCD groups after AM1 hAT-
MSC transplantation, like that noted for p63 after BM-MSC
transplantation in different LSCD models [51, 71]. However,
Reinshagen et al. did not ﬁnd any differences in corneal p63
expression after the transplantation of BM-MSCs in rabbits
with LSCD [40].
Although some authors have proposed the transdifferen-
tiation of MSCs into CK3-expressing corneal epithelial cells
[21, 40, 51, 72], only two have demonstrated that MSCs
transplanted in vivo expressed CK3 in the corneal epithelium
[21, 72]. However, we and other authors have shown that
MSCs express CK3 in normal culture conditions; thus the CK3
expression might not indicate a real transdifferentiation [18,
40]. Our results, together with those obtained by other
authors, indicate that MSCs contribute to the recovery of the
corneal epithelium by secreting factors that act at a paracrine
level rather than by a transdifferentiation process. These fac-
tors would reduce neovascularization and inﬂammation [43,
63] and provide an enabling environment to promote the pro-
liferation and differentiation of the resident stem cells in the
tissues [73, 74]. Although the anti-angiogenic and the anti-
inﬂammatory capacity of hAT-MSCs have been reported
[22–24], this is the ﬁrst time that the capability of these cells
to recover the corneal and limbal phenotypes has been dem-
onstrated in in vivo models.
CONCLUSION
Overall, our results indicate that hAT-MSCs transplanted to
the ocular surface are well tolerated, migrate to inﬂamed
tissues, reduce inﬂammation, restrain the evolution of neo-
vascularization and corneal opaciﬁcation, and partially
restore limbal and corneal epithelial phenotypes. This sug-
gests that hAT-MSC transplantation could be a novel ther-
apy to treat patients suffering from ocular surface failure
due to LSCD. hAT-MSCs represent an efﬁcient source of
stem cells with no availability limitations, and which have
immunomodulatory and regenerative properties that may
provide therapeutic beneﬁts and reduce health care
expenses.
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Table S1. Treatment groups. 
Group (n) LSCD Treatment 
0 (6) None None 
1 (6) Partial None 
2 (3) Partial AM 
3 (6) Partial AM + hAT-MSCs 
4 (6) Total None 
5 (5) Total AM + hAT-MSCs 
n, number of animals; LSCD, limbal stem cell deficiency; AM, amniotic membrane; hAT-MSCs, human 
adipose tissue-derived mesenchymal stem cells. "Partial" refers to the LSCD model that covered 180o and 
included the superior and temporal limbus. "Total" refers to the LSCD that included the entire limbus.  
 
Table S2. Criteria for ocular surface evaluation. 
Score Neovascularization Corneal opacity Epithelial defect Conjunctival  invasion 
0 None None None None 
1 Area ≤ 1/4 Mild Area ≤ 1/4 Area ≤ 1/4 
2 1/4 < area ≤ 1/2 Moderate 1/4 < area ≤ 1/2 1/4 < area ≤ 1/2 
3 1/2 < area ≤ 3/4 Severe, pupil seen faintly 1/2 < area ≤ 3/4 1/2 < area ≤ 3/4 
4 Area > 3/4 Severe, pupil not visible Area > 3/4 Area > 3/4 
 
Table S3. Primary and secondary antibodies used in immunofluorescence experiments. 
Antibody Specificity/Type Clone Source Dilution 
Anti-BrdU-DyLight650 hAT-MSCs marked with BrdU Polyclonal Novus Biologicals 1:100 
Anti-CK3  Corneal epithelial cells AE5 Mp Biomedical 1:50 
Anti-CK7 Conjunctival cells OV-TL 12/30 Vector Laboratories 1:50 
Anti-CK15 Limbal epithelial stem cells LHK15 Merck 1:50 
Anti-E-cadherin Corneal epithelial cells 36 BD Biosciences 1:100 
Anti-p63 Limbal epithelial stem cells 4A4 Santa Cruz 1:50 
Anti-mouse (PECy5) Secondary antibody Polyclonal Santa Cruz 1:100 
Novus Biologicals (Littleton, CO, USA), Mp Biomedical (Illkirch, France), Vector Laboratories (Burlingame, CA, 
USA), Merck (Darmstadt, Germany), BD Biosciences (San Jose, CA, USA), Santa Cruz (Dallas, TX, USA). 
2 
 
Table S4. CK3, E-cadherin, CK15, p63, and CK7 expression in the partial and total limbal stem cell deficiency (LSCD) models. 
  Corneal epithelial cell markers    Limbal stem cell markers    Conjunctival cell marker  
 CK3   E-cadherin   CK15   p63   CK7  
 SL  CC  IL   SL  CC  IL   SL  CC  IL   SL  CC  IL   CJ  SL  CC  IL  
Control  +  +++  +   -  +++  -   +++  -  +++   +++  -  +++   +++  +  -  +  
Partial LSCD  ++  +++  ++   -  +++  -   -  -  +++   -  -  +++   +++  +  -  +  
      AM +  +  +   -  +++  -   -  -  +++   -  -  +++   +++  +  -  +  
      AM + hAT-MSCs +  +++  +   +  +++  -   +++  -  +++   ++  -  +++   +++  +  -  +  
Total LSCD  -  -  -   -  +  -   -  -  -   -  -  -   +++  +  -  +  
      AM + hAT-MSCs ++  +  ++    ++  +++  ++    +++  ++  +++    -  -  ++    +++  +  -  +  
Subjective evaluation: – absence; + mild expression; ++ moderate expression; +++ high expression. AM: amniotic membrane, hAT-MSCs: human adipose tissue-derived mesenchymal stem 
cells, SL: superior limbus, CC: central cornea, IL: inferior limbus, CJ: conjunctiva. 




Supplemental Figure Legends 
Figure S1. Ocular surface evaluation in the partial limbal stem cell deficiency 
(LSCD) model without treatment or transplanted with amniotic membrane (AM). 
Neovascularization (red arrowheads) and corneal opacification developed during the first 
weeks after injury. Epithelial defects partially recovered during the first 2 weeks. There 
were no differences in the clinical signs of the untreated partial LSCD model and the 
partial LSCD model transplanted with AM. Data for week 0 was acquired immediately 
after the partial limbectomy. Data for Week 3 was acquired immediately before 
transplantation. Representative images from animals of each group.  
Figure S2. Inflammatory cells and hAT-MSCs in the ocular surface tissues of partial 
and total limbal stem cell deficiency (LSCD) models. Subjective evaluation: 0, 
absence; 1, low amount; 2, moderate amount; 3, high amount. The size of the points is 
proportional to the relative frequency of animals that belong to each category of the scale. 
There were no differences in the presence of inflammatory cells among the three groups 
of the partial LSCD model. In the total LSCD model, hAT-MSC transplanted eyes had 
fewer inflammatory cells in comparison with the non-transplanted group. The hAT-
MSCs were located in the inflamed areas of the superior and inferior limbal stroma 8 
weeks after transplantation in both partial and total LSCD models. The hAT-MSCs were 
located in the central cornea of the animals with inflammation in this area. The 
correlation between the amount of hAT-MSCs transplanted and the level of inflammation 
in the cornea was significant (r=0.810; p=0.003). AM, amniotic membrane; hAT-MSCs, 
human adipose tissue-derived mesenchymal stem cells. 
 
Figure S3. p63 expression in partial and total limbal stem cell deficiency (LSCD) 
models. In the limbal epithelium of the partial LSCD model, the percentage of p63-
positive cells was significantly lower than in the control healthy group. Very similar 
results were observed in the limbal epithelium of the animals transplanted with cell-free 
AM. Thus there were significant differences with the healthy control group in the total 
limbus and in the superior limbus, but not in the inferior limbus or in comparison with the 
untreated group. The expression of p63-positive cells was significantly lower in the hAT-
MSC transplanted group in comparison with the healthy control group. However, the 
expression of p63 was partially restored in the hAT-MSC transplanted group, especially 
in the superior limbus, where there were significant differences in comparison with the 
untreated group and with the AM transplanted group. In the total LSCD model, the 
percentage of p63-positive cells was significantly lower in the untreated group than in the 
healthy control group. The hAT-MSC transplanted group had a lower percentage of cells 
that expressed p63 than the healthy control group. However, the percentage of p63-
positive cells was partially restored in the hAT-MSC transplanted group, especially in the 
inferior limbus, in comparison with the untreated group. *p≤0.05 and **p≤0.01 in 
comparison with the healthy control group. #p≤0.05 and ##p≤0.01 in comparison with 
the hAT-MSC transplanted group. 
 
Figure S4. Immunofluorescence microscopy of CK7 expression, a conjunctival cell 
marker, in the ocular surface of the partial and total limbal stem cell deficiency 
(LSCD) models at the end of the follow-up period. In healthy control eyes, expression 
of CK7 (yellow) was present in the conjunctival epithelium and in some cells of the 
limbal epithelium. There were no differences in the CK7 expression among the different 
groups within the partial and total LSCD models. Goblet cells mucins in the conjunctiva 
and in the limbus of the healthy eyes were stained by lectin. Additionally, there was a 
diffuse staining on the surface of conjunctival and limbal epithelium, indicating the 
presence of secreted mucins. Except for the central cornea of the total LSCD model, there 
were no differences in lectin staining among the partial or total LCSD groups. In 2 of the 
6 animals with untreated total LSCD, goblet cells were present in the central cornea. 
However, just 1 animal with total LSCD with AM + hAT-MSC transplantation had 
goblet cells in the central cornea. Nuclei, blue. Representative images from each group. 
Scale bar: 100 µm. 
 
